Kymera Therapeutics Inc [KYMR] stock is trading at $25.43, up 5.43%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KYMR shares have gain 15.54% over the last week, with a monthly amount drifted -26.01%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $52. Previously, BTIG Research started tracking the stock with Buy rating on December 10, 2024, and set its price target to $60. On December 06, 2024, BMO Capital Markets initiated with a Market Perform rating and assigned a price target of $55 on the stock. Wells Fargo upgraded its rating to a Overweight but stick to its price target of $57 on December 02, 2024. Stephens initiated its recommendation with a Overweight and recommended $65 as its price target on November 18, 2024. In a note dated August 26, 2024, Wolfe Research upgraded an Outperform rating on this stock but restated the target price of $65.
Kymera Therapeutics Inc [KYMR] stock has fluctuated between $19.44 and $53.27 over the past year. Currently, Wall Street analysts expect the stock to reach $55.33 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $25.43 at the most recent close of the market. An investor can expect a potential return of 117.58% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Kymera Therapeutics Inc [NASDAQ:KYMR] reported sales of 47.07M for the trailing twelve months, which represents a drop of -84.56%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -5.45%, Pretax Profit Margin comes in at -4.76%, and Net Profit Margin reading is -4.76%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.29 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.58 points at the first support level, and at 23.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.92, and for the 2nd resistance point, it is at 26.42.
Ratios To Look Out For
For context, Kymera Therapeutics Inc’s Current Ratio is 7.53. In addition, the Quick Ratio stands at 7.53 and the Cash Ratio stands at 1.77. Considering the valuation of this stock, the price to sales ratio is 35.08, the price to book ratio is 1.97.
Transactions by insiders
Recent insider trading involved Chiniara Ellen, Chief Legal Officer, that happened on Mar 03 ’25 when 2241.0 shares were sold. Chief Operating Officer, Chadwick Jeremy G completed a deal on Mar 03 ’25 to sell 1383.0 shares. Meanwhile, Chief Financial Officer Jacobs Bruce N. sold 7035.0 shares on Mar 03 ’25.
